Senores Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 12, 2025, titled "Senores Pharmaceuticals acquires ANDAs from Teva Pharmaceuticals USA, Inc.".
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals, through its wholly-owned US subsidiary, has signed an agreement to acquire two USFDA-approved generic drug applications (ANDAs) from Teva Pharmaceuticals USA, Inc. The addressable US market opportunity for these products is around USD 38 million (as per IQVIA, MAT December 2024) and approximately USD 120 million (as per Symphony, MAT June 2025). The acquisition will be fully funded from the proceeds of the company's recent IPO, in line with the objects stated in the Red Herring Prospectus. Senores already markets 70 ANDAs and 27 CMO/CDMO products in the US.
The deal deploys IPO funds into revenue-generating US generic assets, potentially expanding Senores' US footprint without additional debt. Shareholders may view this as a positive, value-accretive use of IPO capital that could strengthen future earnings from the US market.